Development of TCR-like antibody and novel chimeric antigen receptor for cancer immunotherapy 

Novel design and combinatory therapy to enhance chimeric antigen receptor engineered T cells (CAR-T) efficacy against solid tumor 

Enhancing the specificity and cytotoxicity of chimeric antigen receptor Natural Killer cells 

Construction and testing of chimeric antigen receptor targeting CS1 for treatment of primary effusion lymphoma 

Comparative analysis of scFv and non-scFv based chimeric antigen receptors (CARs) against B cell maturation antigen (BCMA) 

Generation and characterization of humanized anti-CD19 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Generation and characterization of anti-CD138 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Generation and characterization of fully human anti-CD19 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

Engineering chimeric antigen receptor-directed immune cells for enhanced antitumor efficacy in solid tumors 

Mechanistic model of chimeric antigen receptor T cell activation 

Lym-1 epitope targeted chimeric antigen receptor (CAR) T cells for the immunotherapy of cancer 

Self-secretion of checkpoint blockade enhances antitumor immunity by murine chimeric antigen receptor-engineered T cells 

Improving antitumor efficacy of chimeric antigen receptor-engineered immune cell therapy with synthetic biology and combination therapy approaches 

Engineering chimeric antigen receptor (CAR) -modified T cells for enhanced cancer immunotherapy 

Engineered control of the CAR-T-tumor synapse using customized DNA linkers 

Therapeutic resistance in acute lymphoblastic leukemia: cIAP2 inhibition sensitizes B cell acute lymphoblastic leukemia to anti-CD19 chimeric antigen receptor T cell 

Enhancing the anti-cancer specificity of chimeric antigen receptor T cells through targeting HLA loss 

Enhancing chimeric antigen receptor-engineered immune cell therapy with synthetic biology and nanomedicine 

Engineering therapeutics for the improved antitumor efficacy of chimeric antigen receptor T cell therapy 

Development of an NFAT-GFP Jurkat T cell reporter system for acceleration of T Cell receptor affinity screening 

Engineered CAR-T cells for treatment of solid cancers 

Conjugation of CpG oligodeoxynucleotides to tumor‐targeting antibodies for immunotherapy of solid tumors 

The silenced sentinel: a human papillomavirus type 16 immune evasion mechanism targeting Langerhans cells 

Phospho-proteomic analysis of immune cell activation 

Engineering genetic tools to illustrate new insights into the homeostatic control of synaptic strength